Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : ARDEUT112877
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.23 | |||||
| Debt-to-EBITDA | 1.98 | |||||
| Interest Coverage | 7.02 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.54 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | 13.6 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -13.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 15.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 0.39 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.99 | |||||
| 9-Day RSI | 57.52 | |||||
| 14-Day RSI | 57.06 | |||||
| 6-1 Month Momentum % | 81.52 | |||||
| 12-1 Month Momentum % | 122.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.39 | |||||
| Quick Ratio | 1.28 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 80.98 | |||||
| Days Sales Outstanding | 64.2 | |||||
| Days Payable | 103.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.04 | |||||
| Dividend Payout Ratio | 0.2 | |||||
| 3-Year Dividend Growth Rate | 9.2 | |||||
| Forward Dividend Yield % | 1.37 | |||||
| 5-Year Yield-on-Cost % | 1.47 | |||||
| 3-Year Average Share Buyback Ratio | 2.3 | |||||
| Shareholder Yield % | 10.13 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.01 | |||||
| Operating Margin % | 17.98 | |||||
| Net Margin % | 17.62 | |||||
| ROE % | 24.86 | |||||
| ROA % | 8.24 | |||||
| ROIC % | 8.95 | |||||
| ROC (Joel Greenblatt) % | 135.3 | |||||
| ROCE % | 12.9 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.48 | |||||
| Forward PE Ratio | 7.41 | |||||
| PE Ratio without NRI | 15.48 | |||||
| Shiller PE Ratio | 32.07 | |||||
| Price-to-Owner-Earnings | 11.36 | |||||
| PEG Ratio | 0.82 | |||||
| PS Ratio | 2.73 | |||||
| PB Ratio | 3.8 | |||||
| Price-to-Free-Cash-Flow | 11.54 | |||||
| Price-to-Operating-Cash-Flow | 10.43 | |||||
| EV-to-EBIT | 15.35 | |||||
| EV-to-Forward-EBIT | 8.22 | |||||
| EV-to-EBITDA | 7.63 | |||||
| EV-to-Forward-EBITDA | 7.26 | |||||
| EV-to-Revenue | 3.35 | |||||
| EV-to-Forward-Revenue | 3.28 | |||||
| EV-to-FCF | 14.25 | |||||
| Price-to-Projected-FCF | 0.86 | |||||
| Price-to-DCF (Earnings Based) | 1.04 | |||||
| Price-to-DCF (FCF Based) | 0.73 | |||||
| Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.7 | |||||
| Earnings Yield (Greenblatt) % | 6.52 | |||||
| Forward Rate of Return (Yacktman) % | 29.04 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 8,404,821.304 | ||
| EPS (TTM) (ARS) | 712.458 | ||
| Beta | 0 | ||
| Volatility % | 37.74 | ||
| 14-Day RSI | 57.06 | ||
| 14-Day ATR (ARS) | 417.805894 | ||
| 20-Day SMA (ARS) | 15024.9 | ||
| 12-1 Month Momentum % | 122.45 | ||
| 52-Week Range (ARS) | 7076 - 16915 | ||
| Shares Outstanding (Mil) | 2,089.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bristol-Myers Squibb Co Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(BUE:BMY)'s stock price today?
The current price of BUE:BMY is ARS15136.00. The 52 week high of BUE:BMY is ARS16915.00 and 52 week low is ARS7076.00.
When is next earnings date of Bristol-Myers Squibb Co(BUE:BMY)?
The next earnings date of Bristol-Myers Squibb Co(BUE:BMY) is 2023-10-26 Est..
Does Bristol-Myers Squibb Co(BUE:BMY) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(BUE:BMY) is 1.04% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(BUE:BMY) was 2.57. The lowest was 0.2. And the median was 0.84. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(BUE:BMY) is 1.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers